Melatonin in cancer biology : pathways, derivatives, and the promise of targeted delivery
Melatonin, historically recognized for its primary role in regulating circadian rhythms, has expanded its influence particularly due to its wide range of biological activities. It has firmly established itself in cancer research. To highlight its versatility, we delved into how melatonin interacts with key signaling pathways, such as the Wnt/β-Catenin, PI3K, and NF-κB pathways, which play foundational roles in tumor development and progression. Notably, melatonin can intricately modulate these pathways, potentially affecting various cellular functions such as apoptosis, metastasis, and immunity. Additionally, a comprehensive review of current clinical studies provides a dual perspective. These studies confirm melatonin's potential in cancer management but also underscore its inherent limitations, particularly its limited bioavailability, which often relegates it to a supplementary role in treatments. Despite this limitation, there is an ongoing quest for innovative solutions and current advancements include the development of melatonin derivatives and cutting-edge delivery systems. By synthesizing the past, present, and future, this review provides a detailed overview of melatonin's evolving role in oncology, positioning it as a potential cornerstone in future cancer therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 56(2024), 1 vom: 15. Feb., Seite 62-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yi, Yu-Juan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 16.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/03602532.2024.2305764 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367171996 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367171996 | ||
| 003 | DE-627 | ||
| 005 | 20240216232732.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240116s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2024.2305764 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM367171996 | ||
| 035 | |a (NLM)38226647 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yi, Yu-Juan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Melatonin in cancer biology |b pathways, derivatives, and the promise of targeted delivery |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Melatonin, historically recognized for its primary role in regulating circadian rhythms, has expanded its influence particularly due to its wide range of biological activities. It has firmly established itself in cancer research. To highlight its versatility, we delved into how melatonin interacts with key signaling pathways, such as the Wnt/β-Catenin, PI3K, and NF-κB pathways, which play foundational roles in tumor development and progression. Notably, melatonin can intricately modulate these pathways, potentially affecting various cellular functions such as apoptosis, metastasis, and immunity. Additionally, a comprehensive review of current clinical studies provides a dual perspective. These studies confirm melatonin's potential in cancer management but also underscore its inherent limitations, particularly its limited bioavailability, which often relegates it to a supplementary role in treatments. Despite this limitation, there is an ongoing quest for innovative solutions and current advancements include the development of melatonin derivatives and cutting-edge delivery systems. By synthesizing the past, present, and future, this review provides a detailed overview of melatonin's evolving role in oncology, positioning it as a potential cornerstone in future cancer therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Melatonin | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a delivery | |
| 650 | 4 | |a derivatives | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a signaling pathways | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 700 | 1 | |a Tang, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Pi, Peng-Lai |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Han-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Si-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Wei-Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zi-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Zheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d 1973 |g 56(2024), 1 vom: 15. Feb., Seite 62-79 |w (DE-627)NLM000049530 |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:1 |g day:15 |g month:02 |g pages:62-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/03602532.2024.2305764 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 1 |b 15 |c 02 |h 62-79 | ||